Compare AbbVie Inc (ABBV) vs Transocean Ltd (RIG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AbbVie Inc vs Transocean Ltd — how do they compare? AbbVie Inc trades at $247.61 (market cap $441.94B), while Transocean Ltd trades at $5.72 (market cap $6.49B). The key difference: AbbVie Inc is far larger — about 68.1× Transocean Ltd's market cap, and AbbVie Inc pays a 2.77% dividend while Transocean Ltd pays none. Which is the better fit depends on your goals.
| ABBV | RIG | |
|---|---|---|
Market Cap | $441.94B | $6.49B |
Sector | Health | Technology |
52-Week High | $263.58 | $7.58 |
52-Week Low | $197.38 | $2.80 |
Enterprise Value | $506.19B | $11.10B |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $249.9, up 0.8% on the day, with strong analyst support (29 Buy, 1 Sell) and a $278.69 consensus price target. Recent quarterly earnings have consistently beaten estimates, driven by robust immunology drug sales. The stock shows a bullish technical trend, supported by moving averages, and the company maintains solid cash flow and dividend payments.
Outlook is positive with revenue growth and pipeline advancements, though high P/E and debt levels pose risks. The stock offers a compelling buy case for growth and income investors, balanced by execution and patent expiry challenges ahead.
Transocean Ltd. (RIG) trades at $5.68, down 0.7% on the day. The stock shows a bullish technical signal with strong moving average support, though the RSI suggests mild overbought conditions. Fundamentally, the company reported a Q2 2026 earnings beat but continues to post net losses, with a negative net income margin of -40.24%. Revenue remains stable near $4.1 billion, and the pending Valaris merger offers growth potential. Analyst sentiment is mixed but leans positive, with 39% recommending buy.
The outlook for RIG hinges on operational improvements and merger synergies, but persistent losses and high debt pose significant risks. Investors should weigh the potential upside from contract wins and fleet utilization against the company's current unprofitability and leverage.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Transocean Ltd
Transocean Ltd. is a leading international provider of offshore contract drilling services for oil and gas wells. The company operates one of the world's most versatile fleets of mobile offshore drilling units, including ultra-deepwater drillships and harsh environment semi-submersibles. RIG's services are essential to energy exploration and production companies seeking to access deepwater and challenging reserves globally.
Read more on RIG →
